Clinical Prognostic Score for Predicting Disease Remission with Differentiated Thyroid Cancers

Area of Science:

• Endocrinology
• Oncology
• Medical Statistics

Background:

• Differentiated thyroid cancer (DTC) is a common endocrine malignancy with a generally favorable prognosis.
• Effective long-term outcome prediction is crucial for optimizing patient management strategies.
• This study aimed to develop and validate a clinical prognostic score for DTC remission prediction.

Purpose of the Study:

• To develop a novel clinical prognostic score for predicting disease remission in differentiated thyroid cancer patients.
• To validate the predictive accuracy of the developed score in an independent cohort.
• To provide a tool for personalized decision-making in DTC treatment.

Main Methods:

• A retrospective cohort study involving 1,217 DTC patients from two tertiary-care hospitals in Northeast Thailand.
• Cox proportional-hazards analysis was used to identify independent prognostic factors in 852 patients (development cohort).
• A weighted scoring system was created and validated in 365 patients (validation cohort).

Main Results:

• Five independent prognostic factors were identified: duration from surgery to 131I treatment, distant metastasis, postoperative thyroglobulin level, anti-thyroglobulin antibodies, and TSH suppression adequacy.
• A clinical prognostic score was developed, categorizing patients into low, intermediate, and high risk for disease remission (83%, 87%, and 93% remission rates, respectively).
• The model demonstrated good predictive performance with a concordance index (C-index) of 0.761.

Conclusions:

• The developed clinical prognostic scoring model effectively quantifies the probability of disease remission in DTC.
• This scoring system serves as a valuable tool for personalized treatment decisions in DTC management.
• The model facilitates risk stratification and aids clinicians in tailoring therapeutic strategies for individual patients.